Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects
Bitget2026/09/30 20:01- Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects.
- Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment.
- The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
![Fu Peng: Pay attention to the potential shift in copper from stockpiling to bottleneck logic [Fu Peng Commentary]](https://img.bgstatic.com/external-content/5bba8cd4c8254af78616bb3a2e614b63.jpg?w=420&h=236&f=webp)
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.
SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.
Crypto prices
More
